Efficacy of surufatinib in the treatment of advanced parathyroid carcinoma: A case report
Zhiyong Yu,
Jie Zhou,
Fuqiang Li,
Xiaojun Xie,
Liang Hu,
Linghui Chen,
Xuan Li,
Qijun Zhang,
Junli Wang,
Yijun Wu
Affiliations
Zhiyong Yu
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China; Corresponding author.
Jie Zhou
Department of Pathology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Fuqiang Li
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Xiaojun Xie
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Liang Hu
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Linghui Chen
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Xuan Li
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Qijun Zhang
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Junli Wang
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
Yijun Wu
Department of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China; Corresponding author.
Parathyroid cancer is an extremely rare form of neuroendocrine malignancy. Apart from surgery, the effectiveness of chemotherapy and radiotherapy is limited, and the efficacy of targeted drugs remains unclear. In this study, we demonstrate the therapeutic effectiveness and adverse reaction of the targeted drug surufatinib in treating a case of parathyroid cancer, and concurrently review the recent advancements in the treatment of parathyroid cancer. The patient, a 55-year-old male, underwent his first surgery for a “right cervical mass” in May 2011. Postoperative pathology indicated an atypical adenoma of the parathyroid gland. In August 2016, the patient underwent a second surgery for recurrence of the right cervical tumor, with a pathological diagnosis of parathyroid cancer based on clinical history. In November 2017, the patient underwent a third surgery for recurrence of the right cervical tumor. In December 2017, the patient underwent adjuvant external radiation therapy. In August 2022, the patient developed spinal and lung metastases and underwent spinal surgery. Subsequently, the patient received three rounds of chemotherapy on October 5, 2022, October 28, 2022, and November 18, 2022, but the tumor showed slight enlargement. In January 2023, the patient began treatment with surufatinib. After two cycles of treatment, the tumor showed regression. Given the scarcity of systemic treatment options for parathyroid cancer, the targeted drug surufatinib may offer a promising potential treatment option.
